Abstract
Monoclonal Antibody Therapeutics 2009-2024 - market growth, novel technologies and expansion into new therapeutic areas - our new report examines the significant commercial opportunities
Monoclonal antibodies achieved total sales of nearly $32bn in 2008 and have
grown rapidly to command over 30% of the global biologic drug market. We
expect significant opportunities for further commercial growth from 2009 to
2024, as shown in our new report, Monoclonal Antibody Therapeutics 2009-2024.
New technologies will be an important growth driver. Intensive R&D activity is
producing an exciting antibody pipeline, filled with novel monoclonal
antibodies, antibody fragments and antibody-drug conjugates. Furthermore,
monoclonal antibodies already on the market have scope for additional
development. In particular, visiongain foresees the application of monoclonal
antibodies in new therapeutic areas, outside the currently-established fields.
At the same time, challenges and changes lie ahead. Increased competition for
antibody targets and patient populations, pricing pressures from governments
and other healthcare payers, patent expiry for high-revenue monoclonal
antibodies and the spectre of biosimilar monoclonal antibodies will come to
the fore during the period 2009 to 2024.
What will be the characteristics of drugs that will succeed Avastin and
Remicade, becoming the blockbusters of the future? What are the potential
applications and prospects for antibody fragments? Which pipeline drugs are
the ones to watch? Our completely updated report - packed with 140 tables and
figures - will show you the outlook for this dynamic sector of the
pharmaceutical market.
Comprehensive analysis of the monoclonal antibody therapeutics market
Monoclonal Antibody Therapeutics 2009-2024 examines that sector critically,
through a comprehensive review of information sources, both primary and
secondary. This report provides detailed sales forecasts, discussions of
pipeline developments and analyses of commercial drivers and restraints,
including a SWOT analysis. There are also three detailed interviews with
authorities on the sector in this 200+ page report. The result is a
comprehensive market- and industry-centred study, with detailed analyses and
informed opinion to benefit your work.
Why you should buy this report
By ordering Monoclonal Antibody Therapeutics 2009-2024 you will:
- Find out the market prognosis for the global monoclonal antibody
therapeutics market and for the relevant markets in oncology, autoimmune
disorders and other therapeutic areas from 2009 to 2024
- Receive comprehensive market forecasts and competitive analyses for
leading monoclonal antibodies, including Rituximab, Avastin, Herceptin,
Erbitux, Remicade, Humira, Xolair, Tysabri, Lucentis and Synagis, and for
potential blockbusters of the future
- Read expert views from key-opinion leaders in the monoclonal antibody
field, with full interview transcripts provided
- Examine strengths, weakness, opportunities and threats (SWOT) facing major
stakeholders in the industry, including the prospects for biosimilar
monoclonal antibodies
- Discover market forecasts for the leading monoclonal antibody country
markets and for the emerging markets of China and India
- Analyse the monoclonal antibody therapeutics pipeline, especially for
late-stage candidates, including the prospects for antibody fragments and
antibody-drug conjugates.
| 
View Cart
